there is a spectrum of openness that exists,” says Fan. “The terms of sharing can be legally defined to protect commercial interests while advancing open science.”

A great example is the invention of the CRISPR gene-editing tool. As soon as the papers related to the technology were published, the various research groups involved deposited the plasmids on Addgene, which saw a huge spike in demand for them. Around the globe, thousands of researchers tested the plasmids for all sorts of applications. “I would argue that open sharing in this instance produced data that demonstrated to investors that the technology worked,” adds Fan. In November last year, the world’s first CRISPR gene-editing therapy, Casgevy, was approved in the United Kingdom to treat sickle-cell disease and transfusion-dependent β-thalassaemia.

In research, academic reputations are so highly valued that researchers might be overly cautious about sharing data and methods that are not yet fully reproducible. Mellor suggests that more education around the idea that science is a work in progress could help to convince open-science holdouts. “I am optimistic that as we see more researchers engaging in open science, sharing will become a norm,” he says. “We will see the community driving the open-science movement in the future to achieve reproducible and equitable research.”